Information Journal Paper
APA:
Copy. (2017). Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRα )-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts. American Society of Clinical Oncology; 2017. JOURNAL OF CLINICAL ONCOLOGY, 35(15), 5547-5547. SID. https://sid.ir/paper/755235/en
Vancouver:
Copy. Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRα )-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts. American Society of Clinical Oncology; 2017. JOURNAL OF CLINICAL ONCOLOGY[Internet]. 2017;35(15):5547-5547. Available from: https://sid.ir/paper/755235/en
IEEE:
Copy, “Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRα )-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts. American Society of Clinical Oncology; 2017,” JOURNAL OF CLINICAL ONCOLOGY, vol. 35, no. 15, pp. 5547–5547, 2017, [Online]. Available: https://sid.ir/paper/755235/en